Xenetic Biosciences Inc (XBIO)

NASDAQ
Currency in USD
4.140
-0.060(-1.43%)
Closed
XBIO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
4.0554.260
52 wk Range
2.7805.200
Key Statistics
Edit
Prev. Close
4.14
Open
4.1
Day's Range
4.055-4.26
52 wk Range
2.78-5.2
Volume
12.87K
Average Vol. (3m)
16.99K
1-Year Change
7.29%
Book Value / Share
4.56
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XBIO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year
Show more

Xenetic Biosciences Inc Company Profile

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Compare XBIO to Peers and Sector

Metrics to compare
XBIO
Peers
Sector
Relationship
P/E Ratio
−1.6x−2.3x−0.6x
PEG Ratio
−0.17−0.050.00
Price / Book
0.9x1.0x2.6x
Price / LTM Sales
2.5x15.9x3.1x
Upside (Analyst Target)
-545.2%52.8%
Fair Value Upside
Unlock17.3%8.4%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000

Earnings

Latest Release
Aug 11, 2023
EPS / Forecast
-- / -0.11
Revenue / Forecast
-- / 440.00K
EPS Revisions
Last 90 days

FAQ

What Is the Xenetic Biosciences (XBIO) Stock Price Today?

The Xenetic Biosciences stock price today is 4.14

What Stock Exchange Does Xenetic Biosciences Trade On?

Xenetic Biosciences is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Xenetic Biosciences?

The stock symbol for Xenetic Biosciences is "XBIO."

What Is the Xenetic Biosciences Market Cap?

As of today, Xenetic Biosciences market cap is 6.38M.

What is Xenetic Biosciences Earnings Per Share?

The Xenetic Biosciences EPS is -2.65.

From a Technical Analysis Perspective, Is XBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.